Explore

Rapid Read Rapid Read
GLP-1 Weight-Loss Drugs Show Promise in Treating Obesity-Related Sleep Apnea

GLP-1 Weight-Loss Drugs Show Promise in Treating Obesity-Related Sleep Apnea

A recent review published in JAMA Otolaryngology indicates that GLP-1 weight-loss drugs, such as tirzepatide (marketed as Zepbound and Mounjaro), can significantly reduce the severity of obesity-related obstructive sleep apnea (OSA). Clinical trials included in the review demonstrated that individuals taking tirzepatide experienced 20 to 24 fewer breathing interruptions per hour compared to those on a placebo. Nearly half of the participants achieved remission from OSA. Researchers from the University of Pittsburgh Medical Center suggest that the primary mechanism behind this improvement is weight loss, specifically the reduction of fat in the tongue and around the throat, which helps maintain an open airway during sleep. Obesity is a major contributing factor in most OSA cases, and until recently, no medication directly addressed this aspect of the condition. The U.S. Food and Drug Administration approved Zepbound for moderate to severe OSA in adults with obesity in 2024.
Trendline Trendline
Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential

Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential

Novo Nordisk's Wegovy Shows Promise in Pediatric Obesity Trial, Expanding Market Potential
Rapid Read Rapid Read
GLP-1 Medications Show Promise in Treating Opioid Addiction, Caron Treatment Centers Lead Off-Label Prescriptions

GLP-1 Medications Show Promise in Treating Opioid Addiction, Caron Treatment Centers Lead Off-Label Prescriptions

GLP-1 medications, primarily known for their role in weight-loss management and diabetes treatment, are now being explored for their potential in treating opioid addiction. Dr. Adam Scioli, formerly the chief medical officer and an addictions psychiatrist at Caron Treatment Centers in the United States, has been a key figure in this development. Caron Treatment Centers began prescribing GLP-1s off-label for substance-use disorders in 2024 and has since administered them to over 500 residential clients. While researchers initially cautioned against this approach, Dr. Scioli and his colleagues stand by their decision, citing observed benefits. Early research suggests that GLP-1s may help reduce drug cravings by impacting the brain's dopamine pathway, which is central to both hunger and addiction. Studies, including one at a Caron treatment center, have shown a significant reduction in opioid cravings among participants receiving GLP-1 drugs.
Trendline Trendline
Post-Meal Walks Shown to Moderate Blood Sugar Levels, Supported by Research

Post-Meal Walks Shown to Moderate Blood Sugar Levels, Supported by Research

Post-Meal Walks Shown to Moderate Blood Sugar Levels, Supported by Research
Trendline Trendline
Walking After Meals Significantly Lowers Post-Meal Glucose Levels, Research Shows

Walking After Meals Significantly Lowers Post-Meal Glucose Levels, Research Shows

Walking After Meals Significantly Lowers Post-Meal Glucose Levels, Research Shows
Trendline Trendline
Keto Lifestyle Emphasizes Consistency and Simplicity for Beginners

Keto Lifestyle Emphasizes Consistency and Simplicity for Beginners

Keto Lifestyle Emphasizes Consistency and Simplicity for Beginners
Rapid Read Rapid Read
Dr. Xand van Tulleken Investigates the U.S. Wellness Industry, Highlighting Lack of Scientific Evidence for Most Supplements

Dr. Xand van Tulleken Investigates the U.S. Wellness Industry, Highlighting Lack of Scientific Evidence for Most Supplements

Dr. Xand van Tulleken, a British medic and broadcaster, has published a new book titled 'Make Me Well: A Quest to Understand the Confusing World of Wellness,' which critically examines the U.S. wellness industry. His investigation, prompted by his personal struggles to navigate wellness claims, reveals a significant disconnect between popular wellness products and scientific evidence. Van Tulleken found that while many products are marketed with scientific-sounding claims, these are often not supported by mainstream medical associations or rigorous research. He specifically highlights the case of Vitamin D, which despite widespread belief in its broad health benefits, has been shown in major trials to primarily prevent only Vitamin D deficiency-related diseases like rickets, rather than offering wider health enhancements for the general population. The U.S. supplements business alone is valued at $70 billion annually, with over 100,000 different products expected to be on sale in 2026, indicating a massive...
Reuters Reuters
Novo Nordisk says semaglutide cut obesity rates in young children in trial

Novo Nordisk says semaglutide cut obesity rates in young children in trial

COPENHAGEN, Sept 7 (Reuters) - Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no longer classified as having obesity after 68 weeks, assuming full adherence
Rapid Read Rapid Read
Semaglutide and Tirzepatide Show Potential Anti-Inflammatory Effects Beyond Weight Loss, Novo Nordisk Studies Indicate

Semaglutide and Tirzepatide Show Potential Anti-Inflammatory Effects Beyond Weight Loss, Novo Nordisk Studies Indicate

Clinical studies are revealing that semaglutide and tirzepatide, medications known for glucose control and weight loss, may also reduce systemic inflammation markers in humans. While these GLP-1 agonists are primarily recognized for their metabolic benefits, research suggests a potential anti-inflammatory effect. For instance, the SELECT phase 3 study, conducted by Novo Nordisk, involving 17,600 individuals with overweight or obesity and established cardiovascular disease but without diabetes, showed that semaglutide reduced high-sensitivity C-reactive protein (hsCRP) by approximately 38% compared to a placebo over 104 weeks. This reduction was observed early in the treatment, even before significant weight loss occurred, suggesting that the anti-inflammatory effect might not be solely attributable to weight reduction. Additionally, Novo Nordisk's ESSENCE phase 3 study in patients with MASH (metabolic dysfunction-associated steatohepatitis) and liver fibrosis indicated resolution of steatohepatitis in 63% ...
Trendline Trendline
GLP-1 Weight-Loss Drugs Show Inconsistent Results for Some Patients, Raising Questions About Efficacy and Personal Response

GLP-1 Weight-Loss Drugs Show Inconsistent Results for Some Patients, Raising Questions About Efficacy and Personal Response

GLP-1 Weight-Loss Drugs Show Inconsistent Results for Some Patients, Raising Questions About Efficacy and Personal Response
Rapid Read Rapid Read
Novo Nordisk Announces Positive Results for Semaglutide in Pediatric Obesity Trial

Novo Nordisk Announces Positive Results for Semaglutide in Pediatric Obesity Trial

Novo Nordisk has released the initial findings from its STEP Young phase 3 trial, which evaluated the efficacy of once-weekly semaglutide in combination with lifestyle modifications for children aged 6 to under 12 years with obesity. The trial successfully met its primary endpoint, demonstrating a significant reduction in Body Mass Index (BMI) among children treated with semaglutide compared to those receiving a placebo. Specifically, 40.4% of children in the semaglutide group were no longer classified as having obesity after 68 weeks, whereas none in the placebo group achieved this. Both groups adhered to lifestyle changes, including a reduced-calorie diet and increased physical activity. The safety and tolerability profile of semaglutide in this pediatric population was consistent with previous trials in adults and adolescents, with no new safety concerns identified, including those related to growth or pubertal development. Most participants in the trial had severe obesity (Class II or III) at baseline....
Rapid Read Rapid Read
ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen and ClinPGx Partnership Expands Pharmacogenomics Resources for Precision Medicine

ClinGen, the Clinical Genome Resource, and the Clinical Pharmacogenomics Resource (ClinPGx), which includes the Clinical Pharmacogenetics Implementation Consortium (CPIC), have formed a critical partnership. This collaboration aims to expand ClinGen’s extensive clinical genetics resources to incorporate pharmacogenomics (PGx) knowledge. ClinPGx serves as a primary resource for the PGx research and implementation communities, offering expert-curated gene-drug and variant-drug summaries based on peer-reviewed publications, clinical guidelines, and regulatory drug labels. The partnership facilitates the characterization and dissemination of the clinical relevance of pharmacogenetic variations through transparent and documented Standard Operating Procedures (SOPs). While ClinGen’s Expert Panels focus on gene-disease relationships, ClinPGx specializes in gene-drug and variant-drug associations, providing a comprehensive view of how genetic variations influence drug responses. This integration ensures that pharm...